Sidney Taurel
Sidney Taurel
Sidney Taurelis a Moroccan-born American businessman. He is the former Chairman and Chief Executive Officer of Eli Lilly and Company. He became chief executive officer in July 1998 and chairman of the board of directors on January 1, 1999. He was succeeded as chief executive officer by John C. Lechleiter on April 1, 2008. He now serves as an advisor at Moelis & Company...
data erosion months nearly product prozac sales severe
With nearly two months of Prozac sales data available, the erosion in prescriptions is the most severe ever for a blockbuster product in our industry,
built class financial reputation sound
Through Charlie's leadership, we have built a world-class financial organization and strengthened Lilly's reputation for sound financial operations.
economy growing region resilient seeing seems
We are seeing a very resilient economy and one that seems to be growing in every part of the world. Just about every region is growing and it's very encouraging.
access affordable best care disaster ensure founders health nearly needing patients people survivors values whether
Whether they are patients needing access to affordable health care or survivors of a disaster, we do our best to ensure that people in need are not forgotten. Our founders established these values nearly 130 years ago, and we live by them today.
access increase people poor short
In the short term, I think this will increase access to some people who are not poor enough to be on Medicaid,
ability add area bar behind bench dedication drive increase leadership leaves performance pivotal raise strong throughout transform valued
Charlie's leadership was pivotal in our drive to increase productivity in every part of Lilly. His ability to transform our organization and raise the bar in every area of performance has been invaluable. His dedication to leadership development is also evident. He leaves behind a strong bench of valued leaders who add value throughout the company.
advantage attractive combined enhance focus found offer pcs rite taking value
By taking advantage of this opportunity, Lilly will be able to enhance its focus on pharmaceutical innovation, ... We found Rite Aid's offer attractive because of its value to Lilly and the many synergistic opportunities PCS will have when combined with Rite Aid.
completion confidence continued future high initiation level rapid reflect share
The rapid completion of the share repurchase program, coupled with the initiation of a new program, reflect the board's continued high level of confidence in the future of the company.
lives saving thousands
We're going to be saving hundreds of thousands of lives with this product,
abide actions activities although assure business charged committed continue deeply designed ensuring ethical federal fully governing government highest laws legal practices reflect regret remain resulted seriously standards steps
We deeply regret the 1998 conduct, which has resulted in a federal misdemeanor charge. We take seriously our responsibilities to abide by all the laws governing our business practices and are committed to ensuring our employees' actions reflect the highest legal and ethical standards of conduct. Although the government has not charged Lilly with any unlawful intent, we will continue to take steps designed to assure that Lilly's promotional activities remain fully compliant.
commitment execution faster grow quarter rate reflect results sales strong
Our strong bottom-line results in the first quarter reflect the execution on our commitment to grow sales at a faster rate than our expenses.
existing extensions growth less line next overall product products prozac quarters recent rely sales several
Our overall growth for the next several quarters will be generated from newer product sales, line extensions of existing products and recent product launches, ... As a result, we will rely less on Prozac sales growth.
adjusted anticipate average compared consensus deliver double earnings expect expected fact forecast given growth major nearly patent per rate represents rest share street sustained uniquely wall
Given our products, pipeline, and the fact that we expect no major patent expirations for the rest of this decade, Lilly is uniquely positioned to deliver sustained earnings growth. For 2006, we anticipate earnings per share of $3.10 to $3.20, which represents 8% to 12% growth compared with expected 2005 adjusted earnings. This growth rate is nearly double the average Wall Street consensus forecast for large-cap pharmaceutical companies.
earnings forward grow growth looking percent products share
Looking forward to 2006, our newer products should grow to about 24 percent of revenues and earnings per share should grow 8 to 11 percent, representing top-tier growth for large-cap pharmaceutical companies.